A Physician’s View on an Industry That Misdiagnosed Its Own Health

Markets have vital signs too.

They quicken when hype floods the bloodstream, cool when regulation constricts flow, and crash when they forget what’s worth sustaining.

The cannabis economy, right now, feels like a patient in metabolic crisis — too much sugar, not enough oxygen.

We watched the fever rise in real time. Valuations spiked to thirty-seven billion dollars.

Then came the crash — eleven billion left standing.

Oversupply, 280E tax asphyxia, debt toxicity, investor anemia.

A body flooded with inputs but starved of integration.

When I look at those numbers, I don’t see a “market correction.”

I see a fever breaking.

Because every overheated system, whether biological or financial, burns through what it doesn’t understand.

And this market — for all its talk of scale, margins, and growth — never understood its most vital organ: the patient.

The industry chased profits like adrenaline. But adrenaline doesn’t heal — it just keeps you running until you collapse.

Meanwhile, the patients — the ones whose pain, anxiety, inflammation, and sleeplessness justified legalization in the first place — were treated as anecdotes, not evidence.

They became props in marketing decks instead of partners in innovation.

When that happens in medicine, we call it malpractice.

When it happens in an economy, we call it volatility.

But the mechanism is the same — feedback ignored, symptoms dismissed, homeostasis lost.

You can see it in every price collapse and every shelf of identical gummies.

The body of the market is trying to purge what’s unaligned with its purpose.

Inflammation becomes contraction; fever becomes reset.

And like any body that’s been running on fumes, recovery starts not with more energy, but with listening.

Part II — The Diagnosis: Efficacy Lost, Empathy Missing

Patients don’t buy cannabis for fun.

They buy it for function — sometimes for survival.

I’ve sat with thousands of people who approach this plant not as a lifestyle accessory, but as a last attempt at equilibrium.

A veteran who can’t sleep without reliving trauma.

A teacher who needs her hands to stop shaking before she can hold a pen.

A grandmother who wants to watch her grandkids grow without being crushed by painkillers.

When they walk into a dispensary and find rows of candy-colored packaging but no trustworthy map to relief, that’s not consumer confusion — that’s medical neglect.

It’s the same despair a patient feels when handed a pill bottle with the label smudged off.

Somewhere between seed and sale, the connection between biochemistry and care got severed.

We stopped talking about how cannabinoids modulate neurotransmission or dampen inflammatory cascades, and started talking about “vibes.”

We reduced complex pharmacology to flavor notes.

That’s like a cardiologist describing a medication as “heart-forward with a peppery finish.”

It’s not wrong — it’s just irrelevant.

The myth that cannabis is just another consumer good has become the market’s greatest blind spot.

Because patients are not whimsical spenders — they are feedback mechanisms.

When products fail to deliver, they signal distress through the only lever the market lets them pull: price.

Cheapness isn’t the goal. It’s the symptom.

A body deprived of nourishment will crave sugar; a market deprived of efficacy will chase discounts.

Each time a patient says, “It didn’t help,” that’s data the industry doesn’t know how to read.

Each “I didn’t feel anything” is a market signal screaming, “You’re not listening.”

If we treated those experiences like lab results, the whole economy would look different.

Product design would follow physiology — not trends.

Formulation would follow receptor dynamics — not branding agencies.

And “innovation” would mean better relief, not another flavor drop.

The irony is brutal and beautiful: the more medical we make this plant, the healthier the market becomes.

Because nothing creates loyalty like efficacy. Nothing sustains margins like trust.

The cannabis industry doesn’t have a demand problem.

It has a meaning problem.

Until it rediscovers why people use cannabis — not to escape, but to regulate, to reconnect, to repair — it will keep misdiagnosing its own symptoms.